Market Research Logo

Male Health Drug Development Pipeline Review, 2017

Male Health Drug Development Pipeline Review, 2017

Summary

Male hypogonadism is characterized by androgen deficiency and infertility. Hypogonadism can be caused by disorders at the hypothalamic or pituitary level (hypogonadotropic forms) or by testicular dysfunction (hypergonadotropic forms). There are a total of 23 products in development for this indication, by 19 companies and one academic institution. Key companies operating in this pipeline space include Lipocine, M et P Pharma, Repros Therapeutics and TesoRx Pharma.

Erectile dysfunction is defined as the inability to achieve and maintain an erection sufficient to permit satisfactory intercourse. There are a total of 36 products in development for this indication, by 31 companies and two academic institutions. Key companies operating in this pipeline space include Mitsubishi Tanabe Pharma, Futura Medical, Monosol Rx and NAL Pharmaceuticals.

Finally, Benign prostatic hyperplasia is characterized by age-related hyperplasia of the prostate gland (with or without glandular enlargement), lower urinary tract symptoms and bladder flow obstruction. There are a total of 29 products in development for this indication, by 26 companies and four academic institutions. Key companies operating in this pipeline space include Chong Kun Dang Pharmaceutical, Nymox Pharmaceutical and Yungjin Pharm.

The most common target for male hypogonadism is the androgen receptor, while phosphodiesterase 5 targets dominate the erectile dysfunction pipeline. Targets for the treatment of benign prostatic hyperplasia are more diverse with a strong presence of both androgen receptor and phosphodiesterase targets.

The report, Male Health Drug Development Pipeline Review, 2017 provides an overview of the male health pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Male Hypogonadism, Erectile Dysfunction and Benign Prostatic Hyperplasia and features dormant and discontinued projects.

Scope

  • Which companies are the most active within the pipeline for male health therapeutics?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in the field of male health?
Reasons to buy
  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration


  • GBI Research Report Guidance
  • Executive Summary
  • Introduction
    • Male Health Report Coverage
    • Male Hypogonadism - Overview
    • Erectile Dysfunction - Overview
    • Benign Prostatic Hyperplasia - Overview
  • Therapeutics Development
    • Male Hypogonadism
      • Pipeline Overview
        • Table figure 1: Number of Products under Development for Male Hypogonadism, H2 2017
        • Table Number of Products under Development for Male Hypogonadism, H2 2017
      • Pipeline by Companies
        • Table figure 2: Number of Products under Development by Companies for Male Hypogonadism, H2 2017
        • Table Number of Products under Development by Companies for Male Hypogonadism, H2 2017
      • Pipeline by Universities/Institutes
        • Table Number of Products under Development Pipeline by Universities/Institutes for Male Hypogonadism, H2 2017
      • Products under Development by Companies
        • Table Products under Development by Companies for Male Hypogonadism, H2 2017
      • Products under Development by Universities/Institutes
        • Table Products under Development by Universities/Institutes for Male Hypogonadism, H2 2017
    • Erectile Dysfunction
      • Pipeline Overview
        • Table figure 3: Number of Products under Development for Erectile Dysfunction, H2 2017
        • Table Number of Products under Development for Erectile Dysfunction, H2 2017
      • Pipeline by Companies
        • Table figure 4: Number of Products under Development by Companies for Erectile Dysfunction, H2 2017
        • Table Number of Products under Development by Companies for Erectile Dysfunction, H2 2017
      • Pipeline by Universities/Institutes
        • Table figure 5: Number of Products under Development Pipeline by Universities/Institutes for Erectile Dysfunction, H2 2017
        • Table Number of Products under Development Pipeline by Universities/Institutes for Erectile Dysfunction, H2 2017
      • Products under Development by Companies
        • Table Products under Development by Companies for Erectile Dysfunction, H2 2017
      • Products under Development by Universities/Institutes
        • Table Products under Development by Universities/Institutes for Erectile Dysfunction, H2 2017
    • Benign Prostatic Hyperplasia
      • Pipeline Overview
        • Table figure 6: Number of Products under Development for Benign Prostatic Hyperplasia, H2 2017
        • Table Number of Products under Development for Benign Prostatic Hyperplasia, H2 2017
      • Pipeline by Companies
        • Table figure 7: Number of Products under Development by Companies for Benign Prostatic Hyperplasia, H2 2017
        • Table Number of Products under Development by Companies for Benign Prostatic Hyperplasia, H2 2017
      • Pipeline by Universities/Institutes
        • Table figure 8: Number of Products under Development Pipeline by Universities/Institutes for Benign Prostatic Hyperplasia, H2 2017
        • Table Number of Products under Development Pipeline by Universities/Institutes for Benign Prostatic Hyperplasia, H2 2017
      • Products under Development by Companies
        • Table Products under Development by Companies for Benign Prostatic Hyperplasia, H2 2017
      • Products under Development by Universities/Institutes
        • Table Products under Development by Universities/Institutes for Benign Prostatic Hyperplasia, H2 2017
  • Therapeutics Assessment
    • Male Hypogonadism
      • Assessment by Target
        • Table figure 9: Number of Products by Targets for Male Hypogonadism, H2 2017
        • Table figure 10: Number of Products by Stage and Targets for Male Hypogonadism, H2 2017
        • Table Number of Products by Stage and Target for Male Hypogonadism, H2 2017
        • Table figure 11: Number of Products by Mechanism of Actions for Male Hypogonadism, H2 2017
        • Table figure 12: Number of Products by Stage and Mechanism of Actions for Male Hypogonadism, H2 2017
        • Table Number of Products by Stage and Mechanism of Action for Male Hypogonadism, H2 2017
      • Assessment by Route of Administration
        • Table figure 13: Number of Products by Routes of Administration for Male Hypogonadism, H2 2017
        • Table figure 14: Number of Products by Stage and Routes of Administration for Male Hypogonadism, H2 2017
        • Table Number of Products by Stage and Route of Administration for Male Hypogonadism, H2 2017
      • Assessment by Molecule Type
        • Table figure 15: Number of Products by Molecule Types for Male Hypogonadism, H2 2017
        • Table figure 16: Number of Products by Stage and Molecule Types for Male Hypogonadism, H2 2017
        • Table Number of Products by Stage and Molecule Type for Male Hypogonadism, H2 2017
    • Erectile Dysfunction
      • Assessment by Target
        • Table figure 17: Number of Products by Top 10 Targets for Erectile Dysfunction, H2 2017
        • Table figure 18: Number of Products by Stage and Top 10 Targets for Erectile Dysfunction, H2 2017
        • Table Number of Products by Stage and Target for Erectile Dysfunction, H2 2017
      • Assessment by Mechanism of Action
        • Table figure 19: Number of Products by Top 10 Mechanism of Actions for Erectile Dysfunction, H2 2017
        • Table figure 20: Number of Products by Stage and Top 10 Mechanism of Actions for Erectile Dysfunction, H2 2017
        • Table Number of Products by Stage and Mechanism of Action for Erectile Dysfunction, H2 2017
      • Assessment by Route of Administration
        • Table figure 21: Number of Products by Routes of Administration for Erectile Dysfunction, H2 2017
        • Table figure 22: Number of Products by Stage and Routes of Administration for Erectile Dysfunction, H2 2017
        • Table Number of Products by Stage and Route of Administration for Erectile Dysfunction, H2 2017
      • Assessment by Molecule Type
        • Table figure 23: Number of Products by Molecule Types for Erectile Dysfunction, H2 2017
        • Table figure 24: Number of Products by Stage and Molecule Types for Erectile Dysfunction, H2 2017
        • Table Number of Products by Stage and Molecule Type for Erectile Dysfunction, H2 2017
    • Benign Prostatic Hyperplasia
      • Assessment by Target
        • Table figure 25: Number of Products by Top 10 Targets for Benign Prostatic Hyperplasia, H2 2017
        • Table figure 26: Number of Products by Stage and Top 10 Targets for Benign Prostatic Hyperplasia, H2
        • Table Number of Products by Stage and Target Benign Prostatic Hyperplasia, H2 2017
      • Assessment by Mechanism of Action
        • Table figure 27: Number of Products by Top 10 Mechanism of Actions for Benign Prostatic Hyperplasia, H2 2017
        • Table figure 28: Number of Products by Stage and Top 10 Mechanism of Actions for Benign Prostatic Hyperplasia, H2 2017
        • Table Number of Products by Stage and Mechanism of Action for Benign Prostatic Hyperplasia H2 2017
      • Assessment by Route of Administration
        • Table figure 29: Number of Products by Routes of Administration for Benign Prostatic Hyperplasia, H2 2017
        • Table figure 30: Number of Products by Stage and Routes of Administration for Benign Prostatic Hyperplasia, H2 2017
        • Table Number of Products by Stage and Route of Administration for Benign Prostatic Hyperplasia, H2 2017
      • Assessment by Molecule Type
        • Table figure 31: Number of Products by Molecule Types for Benign Prostatic Hyperplasia, H2 2017
        • Table figure 32: Number of Products by Stage and Molecule Types for Benign Prostatic Hyperplasia, H2 2017
        • Table Number of Products by Stage and Molecule Type for Benign Prostatic Hyperplasia, H2 2017
  • Companies Involved in Therapeutics Development
    • Male Hypogonadism
      • Antares Pharma Inc
        • Table Male Hypogonadism - Pipeline by Antares Pharma Inc, H2 2017
      • Clarus Therapeutics Inc
        • Table Male Hypogonadism - Pipeline by Clarus Therapeutics Inc, H2 2017
      • EndoCeutics Inc
        • Table Male Hypogonadism - Pipeline by EndoCeutics Inc, H2 2017
      • Ferring International Center SA
        • Table Male Hypogonadism - Pipeline by Ferring International Center SA, H2 2017
      • Lipocine Inc
        • Table Male Hypogonadism - Pipeline by Lipocine Inc, H2 2017
      • M et P Pharma AG
        • Table Male Hypogonadism - Pipeline by M et P Pharma AG, H2 2017
      • Medlab Clinical Ltd
        • Table Male Hypogonadism - Pipeline by Medlab Clinical Ltd, H2 2017
      • Merck & Co Inc
        • Table Male Hypogonadism - Pipeline by Merck & Co Inc, H2 2017
      • Mereo Biopharma Group Plc
        • Table Male Hypogonadism - Pipeline by Mereo Biopharma Group Plc, H2 2017
      • Repros Therapeutics Inc
        • Table Male Hypogonadism - Pipeline by Repros Therapeutics Inc, H2 2017
      • TesoRx Pharma LLC
        • Table Male Hypogonadism - Pipeline by TesoRx Pharma LLC, H2 2017
      • The Female Health Company
        • Table Male Hypogonadism - Pipeline by The Female Health Company, H2 2017
      • Viramal Ltd
        • Table Male Hypogonadism - Pipeline by Viramal Ltd, H2 2017
    • Erectile Dysfunction
      • Apricus Biosciences Inc
        • Table Erectile Dysfunction - Pipeline by Apricus Biosciences Inc, H2 2017
      • Astellas Pharma Inc
        • Table Erectile Dysfunction - Pipeline by Astellas Pharma Inc, H2 2017
      • Biolab Farmaceutica Ltda
        • Table Erectile Dysfunction - Pipeline by Biolab Farmaceutica Ltda, H2 2017
      • Biopharm GmbH
        • Table Erectile Dysfunction - Pipeline by Biopharm GmbH, H2 2017
      • Can-Fite BioPharma Ltd
        • Table Erectile Dysfunction - Pipeline by Can-Fite BioPharma Ltd, H2 2017
      • Fabre-Kramer Pharmaceuticals Inc
        • Table Erectile Dysfunction - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H2 2017
      • Futura Medical Plc
        • Table Erectile Dysfunction - Pipeline by Futura Medical Plc, H2 2017
      • Hanmi Pharmaceuticals Co Ltd
        • Table Erectile Dysfunction - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017
      • Humanetics Corp
        • Table Erectile Dysfunction - Pipeline by Humanetics Corp, H2 2017
      • IntelGenx Corp
        • Table Erectile Dysfunction - Pipeline by IntelGenx Corp, H2 2017
      • Ion Channel Innovations LLC
        • Table Erectile Dysfunction - Pipeline by Ion Channel Innovations LLC, H2 2017
      • iX Biopharma Ltd
        • Table Erectile Dysfunction - Pipeline by iX Biopharma Ltd, H2 2017
      • Mezzion Pharma Co Ltd
        • Table Erectile Dysfunction - Pipeline by Mezzion Pharma Co Ltd, H2 2017
      • Mitsubishi Tanabe Pharma Corp
        • Table Erectile Dysfunction - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017
      • Monosol Rx LLC
        • Table Erectile Dysfunction - Pipeline by Monosol Rx LLC, H2 2017
      • N4 Pharma Plc
        • Table Erectile Dysfunction - Pipeline by N4 Pharma Plc, H2 2017
      • NAL Pharmaceuticals Ltd
        • Table Erectile Dysfunction - Pipeline by NAL Pharmaceuticals Ltd, H2 2017
      • Nanoform Cardiovascular Therapeutics Ltd
        • Table Erectile Dysfunction - Pipeline by Nanoform Cardiovascular Therapeutics Ltd, H2 2017
      • Palatin Technologies Inc
        • Table Erectile Dysfunction - Pipeline by Palatin Technologies Inc, H2 2017
      • Pharmicell Co Ltd
        • Table Erectile Dysfunction - Pipeline by Pharmicell Co Ltd, H2 2017
      • SK Chemicals Co Ltd
        • Table Erectile Dysfunction - Pipeline by SK Chemicals Co Ltd, H2 2017
      • Suda Ltd
        • Table Erectile Dysfunction - Pipeline by Suda Ltd, H2 2017
      • XuanZhu Pharma Co Ltd
        • Table Erectile Dysfunction - Pipeline by XuanZhu Pharma Co Ltd, H2 2017
      • Yangtze River Pharmaceutical Group
        • Table Erectile Dysfunction - Pipeline by Yangtze River Pharmaceutical Group, H2 2017
      • Yungjin Pharm Co Ltd
        • Table Erectile Dysfunction - Pipeline by Yungjin Pharm Co Ltd, H2 2017
    • Benign Prostatic Hyperplasia
      • Addex Therapeutics Ltd
        • Table Benign Prostatic Hyperplasia - Pipeline by Addex Therapeutics Ltd, H2 2017
      • AndroScience Corp
        • Table Benign Prostatic Hyperplasia - Pipeline by AndroScience Corp, H2 2017
      • Aphios Corp
        • Table Benign Prostatic Hyperplasia - Pipeline by Aphios Corp, H2 2017
      • BCWorld Pharm Co Ltd
        • Table Benign Prostatic Hyperplasia - Pipeline by BCWorld Pharm Co Ltd, H2 2017
      • Biolab Farmaceutica Ltda
        • Table Benign Prostatic Hyperplasia - Pipeline by Biolab Farmaceutica Ltda, H2 2017
      • Chong Kun Dang Pharmaceutical Corp
        • Table Benign Prostatic Hyperplasia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017
      • Curadis GmbH
        • Table Benign Prostatic Hyperplasia - Pipeline by Curadis GmbH, H2 2017
      • Dongkook Pharmaceutical Co Ltd
        • Table Benign Prostatic Hyperplasia - Pipeline by Dongkook Pharmaceutical Co Ltd, H2 2017
      • GL Pharm Tech Corp
        • Table Benign Prostatic Hyperplasia - Pipeline by GL Pharm Tech Corp, H2 2017
      • Health Ever Bio-Tech Co Ltd
        • Table Benign Prostatic Hyperplasia - Pipeline by Health Ever Bio-Tech Co Ltd, H2 2017
      • Jeil Pharmaceutical Co Ltd
        • Table Benign Prostatic Hyperplasia - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2017
      • MEI Pharma Inc
        • Table Benign Prostatic Hyperplasia - Pipeline by MEI Pharma Inc, H2 2017
      • Meiji Seika Pharma Co Ltd
        • Table Benign Prostatic Hyperplasia - Pipeline by Meiji Seika Pharma Co Ltd, H2 2017
      • Mezzion Pharma Co Ltd
        • Table Benign Prostatic Hyperplasia - Pipeline by Mezzion Pharma Co Ltd, H2 2017
      • Nymox Pharmaceutical Corp
        • Table Benign Prostatic Hyperplasia - Pipeline by Nymox Pharmaceutical Corp, H2 2017
      • Ono Pharmaceutical Co Ltd
        • Table Benign Prostatic Hyperplasia - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
      • OPKO Health Inc
        • Table Benign Prostatic Hyperplasia - Pipeline by OPKO Health Inc, H2 2017
      • SK Chemicals Co Ltd
        • Table Benign Prostatic Hyperplasia - Pipeline by SK Chemicals Co Ltd, H2 2017
      • Sophiris Bio Inc
        • Table Benign Prostatic Hyperplasia - Pipeline by Sophiris Bio Inc, H2 2017
      • Sun Pharma Advanced Research Company Ltd
        • Table Benign Prostatic Hyperplasia - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017
      • The Female Health Company
        • Table Benign Prostatic Hyperplasia - Pipeline by The Female Health Company, H2 2017
      • XuanZhu Pharma Co Ltd
        • Table Benign Prostatic Hyperplasia - Pipeline by XuanZhu Pharma Co Ltd, H2 2017
      • Yungjin Pharm Co Ltd
        • Table Benign Prostatic Hyperplasia - Pipeline by Yungjin Pharm Co Ltd, H2 2017
      • Yuyu Pharma Inc
        • Table Benign Prostatic Hyperplasia - Pipeline by Yuyu Pharma Inc, H2 2017
  • Dormant Projects
    • Male Hypogonadism
      • Table Male Hypogonadism - Dormant Projects, H2 2017
    • Erectile Dysfunction
      • Table Erectile Dysfunction - Dormant Projects, H2 2017
    • Benign Prostatic Hyperplasia
      • Table Benign Prostatic Hyperplasia - Dormant Projects, H2 2017
  • Discontinued Products
    • Male Hypogonadism
      • Table Male Hypogonadism - Discontinued Products, H2 2017
    • Erectile Dysfunction
      • Table Erectile Dysfunction - Discontinued Products, H2 2017
    • Benign Prostatic Hyperplasia
      • Table Benign Prostatic Hyperplasia - Discontinued Products, H2 2017
  • Product Development Milestones
    • Male Hypogonadism
      • Featured News & Press Releases
    • Erectile Dysfunction
      • Featured News & Press Releases
    • Benign Prostatic Hyperplasia
      • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report